![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial |
Tadakazu Hisamatsu, Reiko Kunisaki, Shiro Nakamura, Tomoyuki Tsujikawa, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Kaoru Yokoyama, Masakazu Nagahori, Takanori Kanai, Makoto Naganuma, Hirofumi Michimae, Akira Andoh, Akihiro Yamada, Tadashi Yokoyama, Noriko Kamata, Shinji Tanaka, Yasuo Suzuki, Toshifumi Hibi, Mamoru Watanabe, |
Intest Res. 2018;16(3):494-498. Published online July 27, 2018 DOI: https://doi.org/10.5217/ir.2018.16.3.494 |
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis P440 Loss of response and dose escalation of infliximab and adalimumab in Ulcerative Colitis patients: A Systematic Review and Meta-analysis W1335 Previous Non-Response to Infliximab Predicts Early Dose-Escalation in Adalimumab Treated Crohn's Disease Patients Sa1974 Rational Infliximab De-Escalation in Crohn's Patients in Remission Using Infliximab Levels Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review W1270 Discriminating Between Response Types in Infliximab-Treated Patients With Crohn's Disease: Sensitivity and Specificity of Combined Assessment of Infliximab Trough Levels and Anti-Drug Antibodies Su1225 Concomitant Elemental Diet Therapy Is Effective in Sustaining Infliximab Scheduled Maintenance Therapy in Patients With Crohn's Disease to Prevent Loss of Response Effect of antibodies to infliximab on infusion reaction and clinical response in patients with fistulizing Crohn's disease receiving maintenance treatment with infliximab Sa2049 One Third of Patients Treated With Adalimumab or Infliximab for Crohn's Disease or Ulcerative Colitis Permanently Dose-Escalate Due to Loss of Response |